medigraphic.com
ISSN 0016-3813 (Print)

2008, Number 5

<< Back Next >>

Gac Med Mex 2008; 144 (5)

Mujer de 24 años con neoplasias múltiples en sistema nervioso central

Alvarado-Tobías M, García-López R, Tena-Suck ML, Rembao-Bojórquez D, Gómez-López M, Castillejos-López MJ, López-Hernández CM, Salinas-Lara C

Language: Spanish
References: 15
Page: 441-444
PDF size: 143.30 Kb.


Text Extraction

No abstract


REFERENCES

  1. Reynolds RM, Browning GGP, Nawroz I, Campbell IW. Von Recklinghausen’s neurofibromatosis: Neurofibromatosis type 1. Lancet 2003;361:1552-1554.

  2. Hirsch NP, Murphy A, Radcliffe JJ. Neurofibromatosis: Clinical presentations and anaesthetic implications. Lancet 2001;86:555-564.

  3. Korf BR. Diagnosis and management of neurofibromatosis type 1. Curr Neurol Neurosci Rep 2001;1:162-167.

  4. Huson SM. What level of care for the neurofibromatoses? Lancet 1999;353: 1114-1116.

  5. Lutchman M, Rouleau GA. Neurofibromatosis type 2: A new mechanism of tumour suppression. Trends Neurosci 1996;19:373-377.

  6. Davis RL. Neurofibromin progress on the fly. Nature 2000;403:846-847.

  7. Drouet A, Wolkenstein P, Lefaucher JP, Pinson S, Combemale P, Gherardi, R. K, et al. Neurofibromatosis 1—asocciated neuropathies: A reappraisal. Brain 2004;127:1993-2009.

  8. Leroy K, Dumas V, Martin-Garcia N, Falzone MC, Voisin MC, Wechsler J, et al. Malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1: A clinicopathologic and molecular study of 17 patients. Arch Dermatol 2001;137:908-913.

  9. Sainio M, Jääskeläinen J, Pihlaja H, Carpén O. Mild familiar neurofibromatosis 2 associates with expression of merlin with altered COOOH-terminus. Neurology 2000;54:1132-1138.

  10. Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 1993;363:515-521.

  11. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor supressor. Cell 1993;72:791-800.

  12. Baser ME, Friedman JM, Wallace AJ, Ramsden RT, Joe H, Evans DGR. Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology 2002;59:1759-1765.

  13. Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, et al. A clinical study of type 2 neurofibromatosis. Q J Med 1992;84:603-618.

  14. Guttman DH. Molecular insights into the neurofibromatosis 2. Neurobiol Dis 1997;3:247-261.

  15. Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997;278:51-57.




2020     |     www.medigraphic.com